Related Experiment Video
Updated: Jun 18, 2026
Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia
Published on: January 27, 2018
Alefacept for severe alopecia areata: a randomized, double-blind, placebo-controlled study
Bruce E Strober1, Kavita Menon, Amy McMichael
1Department of Dermatology, New York University Medical Center, 550 First Ave, TCH-158, New York, NY 10016, USA. strober@nyc.rr.com
Objective:
To assess the efficacy of alefacept for the treatment of severe alopecia areata (AA).
Design:
Multicenter, double-blind, randomized, placebo-controlled clinical trial.
Setting:
Academic departments of dermatology in the United States.
Participants:
Forty-five individuals with chronic and severe AA affecting 50% to 95% of the scalp hair and resistant to previous therapies. Intervention Alefacept, a US Food and Drug Administration-approved T-cell biologic inhibitor for the treatment of moderate to severe plaque psoriasis. Main Outcome Measure Improved Severity of Alopecia Tool (SALT) score over 24 weeks.
Results:
Participants receiving alefacept for 12 consecutive weeks demonstrated no statistically significant improvement in AA when compared with a well-matched placebo-receiving group (P = .70). Conclusion Alefacept is ineffective for the treatment of severe AA.
